Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response

ABSTRACT: Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response

PROVIDER: PRJNA1139798 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Interferon-gamma signaling promotes melanoma progression and metastasis

Project description:To investigate the effect of Interferon-gamma signaling on gene expression in melanoma cells We performed gene expression analysis of mouse melanoma cell lines that have been treated with Interferon-gamma cytokine as compared with mock-treated controls.

2022-10-08 | GSE214873 | GEO

Interferon-gamma signaling promotes melanoma progression and metastasis

Project description:Interferon-gamma signaling promotes melanoma progression and metastasis

| PRJNA887440 | ENA

An interferon gamma response signature links myocardial aging and immunosenescence

Project description:An interferon gamma response signature links myocardial aging and immunosenescence

| PRJNA896939 | ENA

Expression via microarray of total RNA isolated from B16 murine melanoma cells stimulated with Interferon-gamma versus untreated controls.

Project description:Functional in vitro studies revealed changes in B16 melanoma migration and proliferation when exposed to Interferon-gamma.

2019-01-31 | E-MTAB-6372 | biostudies-arrayexpress

Conserved interferon-gamma signaling and decreased immune exclusion programs in responses to immune checkpoint blockade therapy

Project description:We analyzed baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4). Analysis of whole transcriptome data showed that T cell infiltration and interferon-gamma signaling signatures corresponded most highly with clinical response to therapy, with a reciprocal decrease in cell cycle and WNT signaling pathways in responding biopsies. Clinical outcome differences were likely not due to differential melanoma cell responses to interferon-gamma, as 57 human melanoma cell lines exposed in vitro to this cytokine showed a conserved interferon-gamma transcriptome response unless they had mutations that precluded signaling from the interferon-gamma receptor. Therefore, the magnitude of the antitumor T cell response and the corresponding downstream interferon-gamma signaling are the main drivers of clinical response or resistance to immune checkpoint blockade therapy.

| EGAS00001004545 | EGA

MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2

Project description:Immunotherapy revolutionized the treatment of advanced melanoma. As the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma patients that received PD-1 blockade (n=36) or adoptive cell therapy with tumor infiltrating lymphocytes (n=37). We identified two melanoma-intrinsic mutually exclusive gene programs, which are controlled by interferon-γ and MYC, and determine immunotherapy outcome. MYC-overexpressing melanoma cells exhibited lower interferon-γ responsiveness, which was linked with JAK2 downregulation. Luciferase activity assays under the control of JAK2 promoter demonstrated reduced activity in MYC-overexpressing cells, which was reversible upon mutagenesis of MYC E-box binding sites in the JAK2 promoter. Moreover, silencing of MYC or its co-factor MAX with siRNA increased JAK2 expression and interferon-γ responsiveness of melanomas, while concomitantly enhancing the effector functions of T-cells co-incubated with MYC-overexpressing cells. Thus, we propose that MYC plays a pivotal role in immunotherapy resistance through downregulation of JAK2.

2023-04-24 | GSE160638 | GEO

Expression data from A375 melanoma cells treated with Interferon-gamma and silvestrol

Project description:Expression data from A375 melanoma cells treated with Interferon-gamma and silvestrol

| PRJNA485934 | ENA

Expression data from A375 melanoma cells treated with Interferon-gamma and silvestrol

Project description:Identify transcriptionnaly and translation regulated RNA by Interferon-gamma and silvestrol

2018-11-23 | GSE118521 | GEO

Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy

Project description:Melanoma dedifferentiation has been reported as a state of cellular resistance to targeted therapies and immunotherapies as cancer cells revert to a more primitive cellular phenotype. Here we show that, counterintuitively, the biopsies of patient tumors that respond to anti-programmed cell death receptor 1 (PD-1) therapy decreased expression of melanocytic markers and increased neural crest markers, suggesting treatment-induced dedifferentiation. When modeling the effects in vitro, we documented that melanoma cell lines that were originally melanocytic differentiated underwent a process of neural crest dedifferentiation when continuously exposed to interferon gamma (IFNγ), through a global chromatin landscape changes leading to enrichment in specific hyperaccessible chromatin regions. The IFNγ-induced dedifferentiation signature corresponded with improved outcomes in patients with melanoma, challenging the notion that neural crest dedifferentiation is entirely an adverse phenotype.

2021-05-10 | GSE154483 | GEO

Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy

2021-05-10 | GSE152755 | GEO